Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
R. M. S. Wong(University of Southern California), Jeffrey S. Weber(NYU Langone Health), Roy Lau(University of Southern California), Ronaldo Scotland(University of Southern California), Chenhui Wang(Cleveland Clinic Lerner College of Medicine), W. Martin Kast(University of Southern California), Alan J. Korman(Bristol-Myers Squibb (Germany))
Cited by 228
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k